The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of being considered in shortage by the Food and Drug Administration (FDA). While the drugs remain on the shortage list for now,

It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.

After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as "available" on the U.S. Food and Drug Administration's drug shortage list. The change in status comes nearly six months after Novo Nordisk,